Janssen Scientific Affairs, LLC
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$42Mgeneral payments (2019-2025)
$389Kresearch payments (2019-2025)
23,951clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Tremfya $2.5M associated (2023-2025)
- Stelara $686K associated (2023-2025)
- Erleada $496K associated (2023-2025)
- Spravato $463K associated (2023-2025)
- Rybrevant $452K associated (2023-2025)
- Darzalex $313K associated (2023-2025)
- Invega Sustenna $266K associated (2023-2025)
- Tecvayli $257K associated (2023-2025)
- Simponi Aria $254K associated (2023-2025)
- Xarelto $251K associated (2023-2025)
- Imbruvica $174K associated (2023-2025)
- Remicade $170K associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Neil Love | Miami, FL | Medical Oncology | $5,591,000.00 |
| Allan Gibofsky | New York, NY | Rheumatology | $776,321.58 |
| Steven Feldman | Winston Salem, NC | Dermatology | $410,802.22 |
| Neil Niren | Pittsburgh, PA | Dermatology | $361,201.93 |
| Jana Johnson | Sioux Falls, SD | Dermatology | $354,638.82 |
| Gerald Dryden | Louisville, KY | Gastroenterology (Internal Medicine) | $337,603.34 |
| Sudhakar Tumuluri | San Francisco, CA | Rheumatology | $318,440.09 |
| David Cohen | Macon, GA | Dermatology | $293,746.62 |
| Scott Gottlieb | Exton, PA | Dermatology | $271,392.84 |
| Arthur Kornbluth | New York, NY | Gastroenterology (Internal Medicine) | $262,296.86 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.